Number of participants with 'any bleeding' event(s) (WHO grade 1 to 4 or equivalent) ‐ · thrombocytopenia
Pathogen‐reduced platelets may leads to higher number of participants with 'any bleeding' event(s) (WHO grade 1 to… compared with standard platelets (low certainty).
1 finding from 1 review
Number of participants with clinically significant bleeding · thrombocytopenia
Pathogen‐reduced platelets showed no clear difference in number of participants with 'clinically significant' bleeding… compared with standard platelets (moderate certainty).
1 finding from 1 review
Number of participants with 'severe' bleeding event(s) (WHO grade ≥ 3 or equivalent) ‐ · thrombocytopenia
Pathogen‐reduced platelets showed no clear difference in number of participants with 'severe' bleeding event(s) (WHO grade ≥… compared with standard platelets (moderate certainty).
1 finding from 1 review
All‐cause mortality · thrombocytopenia
Pathogen‐reduced platelets showed no clear difference in all‐cause mortality compared with standard platelets (moderate certainty).
1 finding from 1 review
Number of participants with a serious adverse event · thrombocytopenia
Pathogen‐reduced platelets showed no clear difference in number of participants with a serious adverse event compared with standard platelets (moderate certainty).
1 finding from 1 review
Number of participants experiencing platelet refractoriness · thrombocytopenia
Pathogen‐reduced platelets leads to higher number of participants experiencing platelet refractoriness compared with standard platelets (high certainty).
1 finding from 1 review
Number of platelet transfusions per participant up to 30 days from study entry · thrombocytopenia
1 finding from 1 review
Overall survival · Adult patients with myelodysplastic syndromes and thrombocytopenia
1 finding from 1 review
Mortality during study · Adult patients with myelodysplastic syndromes and thrombocytopenia
Thrombopoietin mimetics showed no clear difference in mortality during study compared with placebo (low certainty).
1 finding from 1 review
Transformation to AML · Adult patients with myelodysplastic syndromes and thrombocytopenia
It is very uncertain whether thrombopoietin mimetics changes transformation to AML compared with placebo (very low certainty).
1 finding from 1 review
Incidence of bleeding events · Adult patients with myelodysplastic syndromes and thrombocytopenia
Thrombopoietin mimetics probably leads to lower incidence of bleeding events compared with placebo (moderate certainty).
1 finding from 1 review
Blood transfusion requirements · Adult patients with myelodysplastic syndromes and thrombocytopenia
Thrombopoietin mimetics showed no clear difference in transfusion requirement compared with placebo (low certainty).
1 finding from 1 review
Health‐related quality of life · Adult patients with myelodysplastic syndromes and thrombocytopenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All adverse events · Adult patients with myelodysplastic syndromes and thrombocytopenia
Thrombopoietin mimetics showed no clear difference in all adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · Adult patients with myelodysplastic syndromes and thrombocytopenia
It is very uncertain whether thrombopoietin mimetics changes serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality · patients with solid tumours without thrombocytopenia before chemotherapy
The intervention showed no clear difference in all‐cause mortality (low certainty).
1 finding from 1 review
Intervention not reported
Number of patients with at least one severe/life‐threatening bleeding episode · patients with solid tumours with thrombocytopenia during chemotherapy
1 finding from 1 review
Intervention not reported
Number of treatment cycles with at least one bleeding episode ‐ not measured · patients with solid tumours with thrombocytopenia during chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Number of days on which bleeding occurred ‐ not measured · patients with solid tumours with thrombocytopenia during chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
The amount of bleeding ‐ not measured · patients with solid tumours with thrombocytopenia during chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found